New York, March 3, 2026, 08:38 EST — Premarket
- ImmunityBio shares slipped roughly 1.4% ahead of the open, pulling back after their 6.8% surge the previous session.
- The company has its business update and full-year results call lined up for later Tuesday.
- Investors are zeroing in on ANKTIVA’s sales momentum, watching cash burn and awaiting details on upcoming clinical and regulatory moves.
ImmunityBio slipped roughly 1.4% in premarket action Tuesday, trading at $10.29. Just a day earlier, the stock finished 6.75% higher at $10.44. Huge moves have marked recent sessions; shares have now soared over 400% year-to-date.
Timing is key here. Before the bell, investors have shifted into risk-off mode; U.S. index futures are flashing red. That usually spells early trouble for smaller biotech stocks.
ImmunityBio faces a countdown to a scheduled call just hours from now, one that could juggle near-term expectations around demand, supply, and the pace of expansion funding—without another trip to the markets.
ImmunityBio, headquartered in Culver City, California, plans a conference call at 4:30 p.m. Eastern on Tuesday to discuss business developments, pipeline updates, and to go over its financial results for the year ended Dec. 31, 2025.
ImmunityBio disclosed in an SEC filing last week that ANKTIVA generated about $113 million in net product revenue for the full year 2025. The company wrapped up 2025 holding $242.8 million across cash, cash equivalents, and marketable securities. Executive chairman Patrick Soon-Shiong said, “In under two years from initial FDA approval,” ImmunityBio has established a commercial presence in 33 countries. SEC
In the U.S., ANKTIVA has clearance for use alongside BCG, a bladder-administered treatment originally developed from a TB vaccine, targeting some adults with non-muscle invasive bladder cancer that hasn’t responded to BCG and involves carcinoma in situ.
ImmunityBio wrapped up enrollment last week for its Phase 2 trial evaluating ANKTIVA with BCG against BCG alone in BCG-naïve non-muscle invasive bladder cancer. Interim data pointed to stronger complete-response durability on the combination, according to the company. “The interim results … are encouraging,” Dr. Christopher Pieczonka, a principal investigator, commented in the release. A biologics license application could come by the fourth quarter of 2026, ImmunityBio said, though that’s still a way off. ImmunityBio
Competition in bladder-sparing treatments remains intense. Urology specialists point to Merck’s Keytruda, Ferring’s Adstiladrin, and ANKTIVA as FDA-approved options for high-risk, BCG-unresponsive patients.
The picture could flip in a hurry. ImmunityBio’s journey so far has seen manufacturing questions weigh on it, and the stock’s fast climb leaves it exposed—fresh supply hiccups, weaker demand, or a wave of selling across the sector could easily knock it back.
Traders on Tuesday are poised for details: any fresh signals on sales cadence, comments about BCG reimbursement and supply, and whether management offers clearer boundaries on 2026 spending plans.
